Interference between Venus-A Valve and Anterior Mitral Valve Leaflets after Transcatheter Aortic Valve Replacement: Insight from FEops HEARTguide simulation

1			
2			
3 4	Yong Wang ¹ [†] , Ting Liu ¹ [†] , Ying Zeng ¹ , Nic Debusschere ² , Giorgia Rocatello ² , Sihang Cheng ³ , Ping Li ¹ , Dehui Qian ¹ , Shiyong Yu ¹ , Jun Jin ¹ *		
5			
6 7	1 Department of Cardiology, Institute of Cardiovascular Research, The Second Affiliated Hospital of Army Medical University, Chongqing, China.		
8	2 FEops NV, Ghent, Belgium.		
9	3 Venus Medtech, Hangzhou, China.		
10			
11	Running title: Prosthesis-AML interference following TAVR		
12			
13	† These authors contributed equally to this work.		
14 15 16	* The corresponding author. Jun Jin, Department of Cardiology, Institute of Cardiovascular Research, The Second Affiliated Hospital of Army Medical University, Chongqing, China. E-mail xqyyjinjun@163.com		
17	This manuscript contains 3061 words, 3 Tables and 3 Figures.		
18 19	Keywords: transcatheter aortic valve replacement, anterior mitral leaflet, interference, computer simulation.		
20			
21			
22			
23			

24 Abstract

Background Scarce data exist regarding the occurrence of mitral valve interference after transcatheter aortic valve replacement (TAVR) with Venus-A valve implantation. Several case reports have noted that the anterior mitral leaflet (AML) is mechanically affected by the prosthesis frame, particularly when implanted in a low position. This study aimed to investigate the potential factors influencing the clinical outcomes of AML interference after Venus-A valve implantation.

Methods We retrospectively included 20 severe aortic valve stenosis patients who had undergone 31 TAVR and had been implanted with the Venus-A valve at our hospital between October 2020 and 32 June 2021. Pre- and post-procedural CT scans were used for the FEops HEARTguide simulation. 33 Anatomically influencing factors were measured using the 3mensio software and derived from the 34 FEops HEARTguide. The prosthesis-AML interference (PAI) was defined when it met both of 35 two criteria:1) significant interference and limited AML movement shown by transthoracic or 36 transoesophageal echocardiography, and 2) more than half cell intersection between the simulated 37 Venus-A valve and the reconstructed AML revealed by the FEops HEARTguide. Anatomical 38 factors and clinical outcomes were compared between the PAI and non-PAI groups. 39

40 Results Nine PAI patients and 11 non-PAI cases were identified. PAI was associated with shorter 41 mitral-aortic annulus distance $(2.7\pm1.7 \text{ mm vs } 5.0\pm2.2 \text{ mm}, P = 0.019)$, larger prosthesis valve size (P = 0.013), deeper implantation (12.2±3.3 mm vs 6.2±2.9 mm at non-coronary cusp side, P 42 < 0.001) and less calcification of non-coronary cusp (median calcification score, 52.2 mm³ vs 43 156.0 mm³, P = 0.046). Regarding the clinical impact, PAI was associated with a higher rate of 44 moderate or severe perivalvular leakage before discharge than those associated with the absence 45 of PAI, with no difference in haemodynamic parameters and incidence of adverse events at the 46 30-day and 12-month follow-ups between the groups. 47

48 **Conclusions** Interference between the Venus-A prosthesis valve and AML after TAVR was 49 associated with a shorter mitral-aortic annulus distance, larger prosthesis usage, greater 50 implantation depth, and less calcification of the non-coronary cusp. However, further studies are 51 required to explore its long-term clinical impact.

52 1 Introduction

53 Transcatheter aortic valve replacement (TAVR) is the leading therapeutic strategy for aortic valve replacement in patients with severe symptomatic AS (1). As the anterior mitral annulus is 54 anatomically linked to both the left and non-coronary aortic cusps through a shared fibrous rim 55 (2), the prosthesis frame mechanically interferes with the anterior mitral leaflet (AML), especially 56 when implanted in a low position. Several case reports have reported that deep aortic prosthetic 57 valve implantation may impair adequate AML opening (3,4), even led to direct erosive 58 perforation and infective endocarditis (5-7). However, the existing knowledge about this rarely 59 described complication remains limited. 60

A self-expandable valve purportedly has a higher risk of AML interference than that associated with a balloon-expandable valve owing to its long prosthesis frame [4]. The self-expandable Venus-A valve was the first approved transcatheter heart prosthesis and is the most widely used valve in Mainland China. The design characteristics of the Venus-A valves have

been previously reported in detail (8). Data on mitral valve interference after Venus-A valve 65 implantation are scarce. Patient-specific computational modelling of TAVR with the FEops 66 HEARTguide (FEops nv, Ghent, Belgium) based on pre-procedural dual-source computed 67 tomography (DSCT) could accurately predict device-anatomy interactions between a 68 69 self-expandable transcatheter device model and the surrounding anatomical structures (9-11), in 70 both tricuspid and bicuspid aortic valve anatomy (11-14). Three-dimensional computer models can provide detailed insights to help investigate the interference between the AML and the 71 prosthesis frame. 72

In this exploratory study, we sought to explore prosthesis-AML interference in patients with aortic valve stenosis treated with the Venus-A valve through patient-specific computer simulation.

75 2 Materials and Methods

76 2.1 Patient population

This single-centre, retrospective, observational study included 20 patients with severe aortic 77 stenosis who successfully underwent TAVR at our hospital. All patients who had undergone 78 79 transfemoral TAVR using a first-generation self-expandable Venus-A valve (Venus MedTech Inc., Hangzhou, China), and those who had undergone a second valve implantation (valve-in-valve) 80 81 were excluded. The design characteristics of the Venus-A valves have been previously reported in 82 detail (8). Preprocedural and postprocedural computed tomography scans were performed in 20 and 17 patients, respectively, using DSCT (SOMATOM Definition Flash, Siemens Medical 83 Solutions, Germany). The heart team discussed the indications for TAVR, and the size of the 84 prostheses was determined based on the aortic root DSCT. 85

This study was approved by the Research Ethics Committee of the Second Affiliated Hospital (Xinqiao Hospital) of the Army Military Medical University, and the requirement for informed consent was waived because of its retrospective design.

89 2.2 Data collection

Baseline clinical information, echocardiographic, DSCT, procedural, and clinical follow-up 90 data were collected. All patients underwent echocardiography and electrocardiography before 91 discharge and at both 30-day and 12-month follow-ups. Postprocedural DSCT was performed 6-92 93 12 months after TAVR (mean 8.2 months). DSCT data were retrospectively analysed using the 94 3mensio software (Pie Medical, Bilthoven, Netherlands). The aortic root structure was measured 95 in the 40% systolic phase. The aortic annulus was defined as the virtual basal plane containing the basal attachment of the three aortic cusps. Sizes of the annulus, left ventricular outflow tract, 96 sinotubular junction, and ascending aorta were measured. Aortic valve morphology was recorded 97 using the Sievers classification (15). The aortic valve calcification volume was automatically 98 measured using a calcification threshold of 850 HU. Clinical events were recorded according to 99 Valve Academic Research Consortium-3 (VARC-3) criteria (16). Two experienced sonographers 100 independently checked the position of the TAVR prosthesis and its relationship with the AML, 101 and evaluated the morphology and motion of the AML. The degree of their interaction was graded 102 as follows:0, no interference between prosthesis and AML; 1, interference but the motion of AML 103 was not obviously affected; and 2, significant interference and limited AML movement. The 104 kappa coefficient of agreement was 0.92. Prosthesis AML interference (PAI) was defined if met 105

both of the 2 criteria:1) significant interference and limited AML movement shown by
 transthoracic or transoesophageal echocardiography, and 2) more than half-cell intersection
 between the simulated Venus-A valve and the reconstructed AML revealed by computer
 simulation.

110 **2.3 Computer simulation**

Briefly, preprocedural and postprocedural CT scans were obtained from 20 and 17 patients, 111 respectively. Preprocedural cardiac CT images were used to reconstruct finite element models of 112 the aortic root, including native calcified aortic leaflets, left ventricle, left atrium, and mitral 113 leaflets (Figure 1a-1b-1c). Different material properties were used to model the native aortic wall 114 (E=0.6 MPa, v=0.3), native leaflet tissue (E=2 MPa, v=0.45) and calcium nodules (E=4 MPa, 115 v=0.3, Yield stress = 0.6 MPa) (9,10). The left ventricle, left atrium, and mitral leaflets were used 116 for visualisation purposes only to evaluate the interference between the AML and simulated 117 device. Therefore, no material properties are assigned to these structures. 118

In the finite element analysis simulation, the crimped Venus-A valve model was positioned coaxially within the aortic root and deployed by retracting the sheath. In each simulation, the device size and position were consistent with those used in the clinical procedure. Device implantation was iteratively simulated until the final device position matched the actual depth of implantation, as measured from post-procedural CT images in 17 patients (**Figure 1d-1f**). In 3 patients, the final implantation depth at the noncoronary and left coronary cusps was derived from DSA.

126 2.4 Morphological Interference Analysis

The inner linings of the left ventricle and left atrium were segmented from the CT images. The mitral and aortic annuli were manually indicated on CT images. The mitral valve leaflets were reconstructed by mapping a template mesh with the leaflets visible on CT images. The left ventricle, left atrium, and mitral leaflets were used for visualisation purposes only, whereas the aortic annual plane and mitral annulus were used to calculate the mitral-aortic annulus length (distance) and angle.

A reference plane was assigned to each mitral valve (Figure 2), with its origin at the centre 133 of the mitral annulus and its normal vector aligned with the line connecting the posteromedial and 134 135 anterolateral trigones. This plane intersects the mitral and aortic annuli. The mitral-aortic annulus length was defined as the minimum distance between the intersection points. The mitral and aortic 136 annulus normal vectors were defined by determining the best-fitting planes using both closed 137 curves. The mitral-aortic annulus angle was defined as the angle between the respective normal 138 vectors. Morphological interference was defined as more than half of the cells of the Venus A 139 valve intersecting the reconstructed AML in the simulation results. Figure 3 shows two cases with 140 no morphological interference (Figure 3a-3b) and one with morphological interference (Figure 141 3c). Supplementary Figure 1 defined "half-cell intersection". 142

143 2.5 Statistical Analysis

144 Continuous variables with normal distribution are expressed as mean \pm standard deviation; 145 those with skewed distribution are expressed as median (lower and upper quartile), while

146 categorical variables are reported as numbers (proportion). The independent sample *t*-test or 147 Mann-Whitney *U* test was used to compare the means between the two groups, and Fisher's exact 148 test was used for categorical variables. All statistical tests were 2-tailed, with P < 0.05. considered 149 statistically significant. Statistical analyses were performed using SPSS (version 26.0; Chicago, 150 Armonk, NY, USA).

151 **3 Results**

As presented by the FEops HEARTguide, six cases were identified without an intersection between the prosthesis frame and AML (Figure 3a), five had an intersection < half cell (Figure 3b), and nine cases were identified with more than half of the cells (Figure 3c). Consistently, echocardiography showed that all 9 patients with an intersection of more than half of the cells showed significant interference and limited AML movement, whereas those with an intersection <half-cell showed no limited AML movement. Therefore, 9 PAI cases and 11 non-PAI cases were identified.

As shown in **Table 1**, the groups did not differ in terms of sex, age, and other clinical characteristics, while the presence of atrial fibrillation (P = 0.050) and more than mild mitral regurgitation was higher (P = 0.028) in the PAI group. The left ventricular anteroposterior diameter was larger (P = 0.028), while the ejection fraction and fractional shortening were lower in the PAI group (both P < 0.05).

The anatomical characteristics of the patients are shown in Table 2. According to the 164 computer simulation parameters, the length between aortic-mitral annulus was shorter in PAI 165 cases (2.7 \pm 1.7 mm vs 5.0 \pm 2.2 mm, P = 0.019), but the angle showed no difference (Figure 2). 166 According to the CT parameters, PAI was associated with a larger annulus and LVOT (all P 167 <0.05). Nevertheless, less calcification of the non-coronary cusp was observed in the PAI group 168 (P = 0.046). The procedural characteristics and in-hospital clinical outcomes are listed in **Table 3**. 169 The proportion of larger size prosthesis application was higher (P = 0.013), and the implantation 170 depth was significantly deeper in patients with PAI (12.2 ± 3.3 mm vs 6.2 ± 2.9 mm at NCC side, P 171 < 0.001, and 14.3 \pm 4.7 mm vs 7.7 \pm 3.1 mm at LCC side, P = 0.002, respectively). Moreover, the 172 incidence of moderate perivalvular leakage (PVL) was higher in the PAI group (5/9 vs 0/11, P =173 174 0.008). The incidence of new-onset left bundle branch block was higher in the PAI group; 175 however, the difference was not statistically significant (P = 0.070).

176 Regarding clinical outcomes, no significant differences were observed in aortic flow velocity, 177 aortic pressure gradient, or clinical events such as mortality, stroke, PVL, and heart failure 178 between the two groups at both the 30-day and 12-month follow-ups. In particular, we observed 179 special adverse consequences of PAI according to previous reports (3-6), and no new-onset mitral 180 stenosis, infective endocarditis, or mitral valve perforation occurred in either group (**Table 3**).

181 4 Discussion

To our knowledge, this is the first report to explore the anatomical influencing factors and midterm clinical outcomes of PAI following self-expandable TAVR. The Venus-A valve was chosen, and the FEops HEARTguide simulation was used to visually exhibit interference. Additionally, the clinical and haemodynamic outcome parameters were compared between the PAI and non-PAI groups. The results showed that PAI was associated with a shorter mitral-aortic

annulus distance, larger prosthesis valve size, deeper implantation, and less calcification of the
 non-coronary cusp. Moreover, it was associated with a higher rate of moderate or severe
 perivalvular leakage before discharge, but haemodynamic parameters and the incidence of
 adverse events at the 30-day and 12-month follow-ups were not affected.

191 Being in close contact with the left fibrous trigone (2,17), the AML is prone to interference with the prosthetic valve. In fact, our previous study found that in patients with pure native aortic 192 valve regurgitation, 14 of 61 (23.0%) patients who received Venus-A prosthesis implantation had 193 significant PAI following TAVR (18). To some extent, PAI should be considered a common 194 complication (7,19,20), but it has rarely been described and is not covered by the VARC-3 criteria 195 (16). In other words, the lack of consistent definitions and measurement standards in daily clinical 196 practice has hindered the reporting of PAI. This report attempts to draw attention to this neglected 197 clinical complication, which has been excluded from the standardised outcome reports of patients 198 with TAVR. Given that there is currently no standardised definition, in this study, we first propose 199 a diagnostic criterion for PAI that includes both functional and morphological assessments. To 200 precisely describe their interaction visually, we used the FEops HEARTguide based on DSCT for 201 computer simulation. The FEops HEART guide has been previously reported to accurately predict 202 203 the device-anatomy interaction between a self-expandable transcatheter device model and the surrounding anatomical structures (9-11), even in Chinese patients implanted with Venus-A valves 204 (11,21,22). However, previous studies have mainly described the prosthesis frame morphology 205 and complications such as conduction disturbance and PVL after valve implantation. In the 206 present study, we first revealed the interaction between the prosthesis frame and the AML using 207 the FEops HEARTguide. However, because of the limited accuracy of the FEops HEARTguide in 208 patients who underwent valve-in-valve TAVR, this study excluded those subjects, while most 209 valve-in-valve cases were supposed to have PAI in view of their deep implantation. In the future, 210 improvement of the FEops HEARTguide or other technologies, such as 3D printing, may help in 211 the evaluation of these patients. 212

As mentioned previously, deep implantation of a long-frame prosthesis is a significant risk 213 factor for PAI. However, in a recently published case report, AML perforation occurred 214 immediately after balloon predilatation due to folded leaflet calcifications distributed at the level 215 of the non-coronary sinus toward the medial aspect of the mitral-aortic curtain (23). The authors 216 considered that the distribution of bulky calcifications could also play a role in AML injury during 217 TAVR procedure (23). In the present study, we further recognised several other potential risk 218 factors, such as shorter mitral-aortic annulus distance, use of a larger prosthesis valve, and less 219 calcification of the non-coronary cusp. The distance of the mitral aortic annulus varies across 220 patients, and in those with prosthetic mitral valves (PMVs) undergoing TAVR, PMV-to-aortic 221 annulus distances of <7 mm are independent risk factors for value embolization (24). However, 222 we could not provide a threshold value of the mitral-aortic annulus distance for risk stratification 223 given the small sample size in this descriptive and exploratory study. Theoretically, the angle 224 between the aortic/mitral planes should also influence their interference, but we failed to detect a 225 difference in the mitral-aortic annulus angle between the PAI and non-PAI groups (131.4° vs 226 126.2°, P=0.333), which may be partially explained by the limited sample size. A large prosthesis 227 was also supposed to shorten the distance between the AML and the implanted valve frame owing 228 to its wide bottom in the LVOT. Moreover, we noticed that the difference of calcification volume 229 at NCC was statistically significant between the groups, the reason remains speculative, but a 230 possible explanation is that the distribution of eccentric calcification in the aortic valve facilitate 231

medRxiv preprint doi: https://doi.org/10.1101/2023.04.14.23288608; this Preprint preprint line author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

232 deeper implantation (25).

Deep implantation may explain post-procedural PVL and new-onset left bundle branch block, 233 but the adverse impact of PAI on 30-day and 12-month clinical prognoses was not detected in the 234 present study, partially because of the small sample size and relatively short follow-up duration. 235 However, we noticed that the PAI group showed a higher rate of heart failure at the 30-day and 236 12-month follow-ups (4/9 vs 1/11), which may be caused by a higher rate of PVL in the PAI 237 group; the higher rate of concomitant atrial fibrillation at baseline (5/9 vs 1/11) may also worsen 238 cardiac function. A previous study reported five cases of post-TAVR mitral valve stenosis due to 239 PAI, with a mean trans-mitral gradient ranging from 7 mmHg to13 mmHg, three of which were 240 treated with a conservative approach, and two others received urgent surgery (4). In the present 241 study, the trans-mitral gradient remained at <5 mmHg in all PAI cases. This may be explained by 242 the exclusion of valve-in-valve cases, in which patients were supposed to have a more severe 243 impact on AML motion. 244

Nevertheless, the present report calls attention to this common complication regarding the devastating consequences of potential AML perforation, delayed mitral stenosis, and infective endocarditis (4-7). Furthermore, this study also emphasises the need for meticulous patient selection and strategy decision in those with a large annulus, short mitral-aortic annulus distance, and less calcification of the non-coronary cusp. To reduce the risk of PAI, a resheathable or short-frame device may be considered. Patients who may benefit from concomitant percutaneous mitral valve repair should also be carefully evaluated before developing final treatment strategies.

252 4.1 Limitations

The present study had several limitations. First, given the relatively small sample size and 253 retrospective observational design, formal statistical analysis was not performed. Therefore, 254 caution should be exercised when drawing firm conclusions owing to unmeasured confounders. 255 Second, only the first-generation Venus-A valve was used in this study, and its applicability to 256 other devices requires confirmation. However, the Venus-A valve is morphologically similar to 257 the Medtronic CoreValve, and our findings may provide information to those who undergo 258 259 CoreValve device implantation. Second, the HEARTguide is not generally used in clinical 260 practice; simpler detection methods for PAI are needed. Third, other factors, such as extensive 261 calcification of the aorto-mitral continuity or mitral ring, may also increase the risk of PAI and new-onset mitral valve stenosis, while no patients had severe calcification of the aorto-mitral 262 continuity or mitral ring, and this factor was not included in the analysis. Other limitations 263 264 included patient selection bias, short follow-up duration, and lack of an independent core laboratory or adjudication of clinical events. 265

266 5 Conclusions

PAI is associated with a shorter mitral-aortic annulus distance, larger prosthesis usage, deeper implantation, and less calcification of the non-coronary cusp. However, further studies are required to explore its long-term clinical impact.

270 6 Captions

271 Table 1. Baseline characteristics of PAI group and Non-PAI group

272 Data are presented as mean \pm standard deviation or median (lower quartile, upper quartile). PAI,

273 Prosthesis-anterior mitral leaflet interference; NYHA, New York Heart Association; STS, Society

- of Thoracic Surgeons. NCC, Non coronary cusp; RCC, Right coronary cusp; LCC, Left coronary
- 275 cusp.

276 **Table 2.** Intra-Procedural data and in-hospital outcomes of the two groups

277 Data are presented as mean ± standard deviation or median (lower quartile, upper quartile). PAI,

278 Prosthesis-anterior mitral leaflet interference; NYHA, New York Heart Association; STS, Society

of Thoracic Surgeons. NCC, Non coronary cusp; LCC, Left coronary cusp. LBBB, left bundle

- 280 branch block. NA, Not Applicable.
- **Table 3.** The 30-day and 12-month clinical outcomes of the two groups

Data are presented as mean ± standard deviation. PAI, Prosthesis-anterior mitral leaflet
 interference; NYHA, New York Heart Association; NA, Not Applicable.

284

Figure 1. Patient-specific computer simulation workflow. a) Aortic root anatomical structures including native calcified leaflets segmented from preoperative CT images in Mimics (Materialize, Leuven); b,c) Aortic root anatomical structures reconstructed with FEops HEARTguide from frontal and top view respectively; d) segmentation of the VenusA valve based on postoperative CT images in Mimics; e) simulation of the VenusA implantation using FEops HEARTguide; f) evaluation of the interaction between the simulated Venus-A valve and the AML reconstructed with FEops HEARTguide.

292

Figure 2. Definition of mitral-aortic annulus distance (blue line) and mitral-aortic annulus angle. Shown is a reference plane through the center of the mitral annulus with normal vector aligned with the postero-medial and antero-lateral trigones, and the best fitting normal vectors of the mitral annulus and aortic annulus.

297

Figure 3. Representative cases of PAI and non-PAI. a) Case with no intersection between the simulated Venus-A valve and the reconstructed AML resulting in no morphological interference; b) case with limited intersection between the simulated Venus-A valve and the reconstructed AML (intersection <half cell) resulting in no morphological interference; c) case with large intersection between the simulated Venus-A valve and the reconstructed AML (intersection >half cell) resulting in morphological interference.

304

Supplementary Figure 1. Description of half one cell. a) Red arrow indicates one cell,
 yellow arrow indicates half cell. b) Interference less than half cell.

307

medRxiv preprint doi: https://doi.org/10.1101/2023.04.14.23288608; this Preprint preprint 1112223.04.14.23288608; this Preprint in preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

308 8 Author contribution statement

309 YW and TL contributed equally to study design, data acquisition, statistical analysis, and

drafted the manuscript. JJ approved the submission of the final version. YZ, PL, DQ and SY

contributed greatly to data collection and the revision of the manuscript. ND, GR and SC

312 contributed greatly to computer simulation. All authors contributed to the article and approved the

313 submitted version.

314 9 COMPETING INTEREST

Nic Debusschere and Giorgia Rocatello are employees of Feops NV. Sihang Cheng is an employee of Venus Medtech. The other authors report no disclosures of competing interest.

317 10 FUNDING

This work was funded by the Chongqing Talents Project (Jin Jun) and Young Doctor Incubation Program of Xinqiao Hospital (2022YQB094).

320 11 Acknowledgments

We would like to thank Editage (www.editage.cn) for English language editing.

322 12 REFERENCES

[1] Kalogeropoulos, A. S., Redwood, S. R., Allen, C. J., Hurrell, H., Chehab, O., Rajani, R., et al.
(2022). A 20-year journey in transcatheter aortic valve implantation: Evolution to current
eminence. Frontiers in cardiovascular medicine, 9, 971762.

[2] Tsang, W., Meineri, M., Hahn, R. T., Veronesi, F., Shah, A. P., Osten, M., et al. (2013). A
three-dimensional echocardiographic study on aortic-mitral coupling in transcatheter aortic valve
replacement. European heart journal. Cardiovascular Imaging, 14(10), 950-956.
doi:10.1093/ehjci/jet058

330 [3] Franco, E., de Agustín, J. A., Hernandez-Antolin, R., Garcia, E., Silva, J., Maroto, L., et al.

- (2012). Acute mitral stenosis after transcatheter aortic valve implantation. Journal of the
 American College of Cardiology, 60(20), e35. doi:10.1016/j.jacc.2012.05.061
- [4] Cannata, F., Regazzoli, D., Barberis, G., Chiarito, M., Leone, P. P., Lavanco, V., et al. (2019).
 Mitral Valve Stenosis after Transcatheter Aortic Valve Replacement: Case Report and Review of
 the Literature. Cardiovascular revascularization medicine : including molecular interventions,
 20(12), 1196-1202. doi:10.1016/j.carrev.2019.02.023
- [5] Fotbolcu, H., & Özdemir, R. (2022). Multiple Anterior Mitral Valve Perforation After Deep
 Transfemoral Aortic Valve Implantation. Brazilian journal of cardiovascular surgery, 37(4),
 602-604. doi:10.21470/1678-9741-2020-0566

[6] Amat-Santos, I. J., Cortés, C., & Varela-Falcón, L. H. (2017). Delayed left anterior mitral
leaflet perforation and infective endocarditis after transapical aortic valve implantation-Case
report and systematic review. Catheterization and cardiovascular interventions : official journal of

- the Society for Cardiac Angiography & Interventions, 89(5), 951-954. doi:10.1002/ccd.26410
- [7] Miura, M., Isotani, A., Murata, K., Kawaguchi, T., Hayashi, M., Arai, Y., et al. (2016).
 Perforation of Anterior Mitral Leaflet Due to Mechanical Stimulation Late After Transcatheter
 Aortic Valve Replacement. JACC. Cardiovascular interventions, 9(24), e233-e234.
 doi:10.1016/j.jcin.2016.10.009
- [8] Li, J., Sun, Y., Zheng, S., Li, G., Dong, H., Fu, M., et al. (2021). Anatomical Predictors of
 Valve Malposition During Self-Expandable Transcatheter Aortic Valve Replacement. Frontiers in
 cardiovascular medicine, 8, 600356.doi:10.3389/fcvm.2021.600356
- [9] Schultz, C., Rodriguez-Olivares, R., Bosmans, J., Lefèvre, T., De Santis, G., Bruining, N., et
 al. (2016). Patient-specific image-based computer simulation for theprediction of valve
 morphology and calcium displacement after TAVI with the Medtronic CoreValve and the Edwards
 SAPIEN valve. EuroIntervention : journal of EuroPCR in collaboration with the Working Group
 on Interventional Cardiology of the European Society of Cardiology, 11(9), 1044-1052.
 doi:10.4244/EIJV11I9A212
- [10] Rocatello, G., El Faquir, N., De Santis, G., Iannaccone, F., Bosmans, J., De Backer, O., et al.
 (2018). Patient-Specific Computer Simulation to Elucidate the Role of Contact Pressure in the
 Development of New Conduction Abnormalities After Catheter-Based Implantation of a
 Self-Expanding Aortic Valve. Circulation. Cardiovascular interventions, 11(2), e005344.
 doi:10.1161/CIRCINTERVENTIONS.117.005344
- [11] Liu, X., Fan, J., Mortier, P., He, Y., Zhu, Q., Guo, Y., et al. (2021). Sealing Behavior in
 Transcatheter Bicuspid and Tricuspid Aortic Valves Replacement Through Patient-Specific
 Computational Modeling. Frontiers in cardiovascular medicine, 8, 732784.
 doi:10.3389/fcvm.2021.732784
- [12] Dowling, C., Bavo, A. M., El Faquir, N., Mortier, P., de Jaegere, P., De Backer, O., et al.
 (2019). Patient-Specific Computer Simulation of Transcatheter Aortic Valve Replacement in
 Bicuspid Aortic Valve Morphology. Circulation. Cardiovascular imaging, 12(10), e009178.
 doi:10.1161/CIRCIMAGING.119.009178
- [13] Dowling, C., Firoozi, S., & Brecker, S. J. (2020). First-in-Human Experience With
 Patient-Specific Computer Simulation of TAVR in Bicuspid Aortic Valve Morphology. JACC.
 Cardiovascular interventions, 13(2), 184-192. doi:10.1016/j.jcin.2019.07.032
- [14] Dowling, C., Gooley, R., McCormick, L., Firoozi, S., & Brecker, S. J. (2021).
 Patient-specific Computer Simulation: An Emerging Technology for Guiding the Transcatheter
 Treatment of Patients with Bicuspid Aortic Valve. Interventional cardiology (London, England),
 16, e26. doi:10.15420/icr.2021.09
- [15] Sievers, H. H., & Schmidtke, C. (2007). A classification system for the bicuspid aortic valve
 from 304 surgical specimens. The Journal of thoracic and cardiovascular surgery, 133(5),
 1226-1233.doi:10.1016/j.jtcvs.2007.01.039
- 380 [16] VARC-3 WRITING COMMITTEE, Généreux, P., Piazza, N., Alu, M. C., Nazif, T., Hahn, R.
- 381 T., Pibarot, P., et al. (2021). Valve Academic Research Consortium 3: updated endpoint definitions

for aortic valve clinical research. European heart journal, 42(19), 1825-1857. doi:
10.1093/eurheartj/ehaa799

[17] Nappi, F., Nenna, A., Timofeeva, I., Mihos, C., Gentile, F., & Chello, M. (2020). Mitral
regurgitation after transcatheter aortic valve replacement. Journal of thoracic disease, 12(5),
2926-2935. doi:10.21037/jtd.2020.01.69

[18] Wang, Y., Yu, S., Qian, D., Li, J., Fang, Z., Cheng, W., et al. (2022) Anatomic predictor of
severe prosthesis malposition following transcatheter aortic valve replacement with
self-expandable Venus-A Valve among pure aortic regurgitation: A multicenter retrospective study.
Frontiers in cardiovascular medicine, 9:1002071. doi: 10.3389/fcvm.2022.1002071

[19] Raschpichler, M., Seeburger, J., Strasser, R. H., & Misfeld, M. (2014). Corevalve prosthesis
causes anterior mitral leaflet perforation resulting in severe mitral regurgitation and subsequent
endocarditis. European heart journal, 35(24), 1587. doi:10.1093/eurheartj/eht503

[20] Sanna, G. D., Moccia, E., Pepi, M., & Parodi, G. (2020). Anterior Mitral Leaflet Perforation
and Infective Endocarditis Following Transcatheter Aortic Valve Replacement in a Patient
Presenting with Heart Failure. Journal of cardiovascular echography, 30(1), 44–46.
doi:10.4103/jcecho.jcecho_52_19

Xiong, T. Y., Stoppani, E., De Beule, M., Chen, F., Li, Y. J., Liao, Y. B., Feng, Y., de Jaegere,
P., & Chen, M. (2021). Force distribution within the frame of self-expanding transcatheter aortic
valve: Insights from in-vivo finite element analysis. Journal of biomechanics, 128, 110804.
doi:10.1016/j.jbiomech.2021.110804

[22] Han, Y., Ribeiro, J. M., de Jaegere, P. P. T., & Zhang, G. (2021). TAVR in a Patient With
Quadricuspid Aortic Stenosis: The Role of Patient-Specific Computer Simulation in Treatment
Planning and Outcome Prediction. JACC. Cardiovascular interventions, 14(9), e93-e95.
doi:10.1016/j.jcin.2021.01.014

[23] Moldovan, H., Popescu, B. Ş., Nechifor, E., Badea, A., Ciomaga, I., Nica, C., Zaharia, O.,
Gheorghiță, D., Broască, M., Diaconu, C., Parasca, C., Chioncel, O., & Iliescu, V. A. (2022). Rare
Cause of Severe Mitral Regurgitation after TAVI: Case Report and Literature Review. Medicina
(Kaunas, Lithuania), 58(4), 464. doi:10.3390/medicina58040464

[24] Amat-Santos, I. J., Cortés, C., Nombela Franco, L., Muñoz-García, A. J., Suárez De Lezo, J.,
Gutiérrez-Ibañes, E., et al. (2017). Prosthetic Mitral Surgical Valve in Transcatheter Aortic Valve
Replacement Recipients: A Multicenter Analysis. JACC. Cardiovascular interventions, 10(19),
1072 1081 doi:10.1016/j.jcir.2017.07.045

413 1973-1981. doi:10.1016/j.jcin.2017.07.045

[25] Li, L., Liu, Y., Jin, P., Tang, J., Lu, L., et al. (2021). Effect of Eccentric Calcification of an 414 Aortic Valve on the Implant Depth of a Venus-A Prosthesis During Transcatheter Aortic Valve 415 Replacement: А Retrospective Study. Frontiers in physiology, 12, 718065. 416 doi:10.3389/fphys.2021.718065 417

418















	PAI group (n=9)	Non-PAI group (n=11)	P value
Clinical data	•••		
Male gender	3/9	5/11	0.670
Age (yrs)	69.1 ±6.2	72.3 ±7.1	0.302
Body mass index (Kg/m ²)	24.5 ±4.8	25.4±4.3	0.645
Coronary heart disease	2/9	2/11	1.000
Atrial fibrillation	5/9	1/11	0.050*
Hypertension	4/9	5/11	1.000
Diabetes	0/9	2/11	0.479
NYHA class III/IV	7/9	5/11	0.197
STS score (%)	4.5 ±1.6	4.2 ±1.8	0.726
Ultrasound data			
Left atrium anteroposterior diameter (mm)	41.4 ±6.9	37.1±4.9	0.115
Left ventricle anteroposterior diameter (mm)	52.0 ±6.0	45.8 ±4.2	0.015*
Interventricular septum thickness (mm)	12.8±1.4	13.7±2.2	0.283
Ejection fraction (%)	59.9 ±6.0	64.8±3.5	0.039*
Fraction shortening (%)	31.9 ±4.0	35.4 ±2.6	0.036*
Peak aortic flow velocity (cm/s)	466.9 ±58.1	507.6±70.5	0.182
Mean aortic valve pressure gradient (mmHg)	49.0 ±12.9	57.6 ±16.0	0.207
➢Mild mitral regurgitation	8/9	4/11	0.028*
➢Moderate mitral regurgitation	3/9	0/11	0.074
➢Moderate aortic regurgitation	4/9	2/11	0.336
Feops data			
Distance between aortic / mitral planes (mm)	2.7 ±1.7	5.0±2.2	0.019*
Angle between aortic / mitral planes (degree)	131.4±11.6	126.2±11.5	0.333
CT data			
Bicuspid	5/9	7/11	1.000
Туре О	4/5	3/7	
Type 1	1/5	4/7	
Aortic annulus			
Mean diameter (mm)	24.2 ±1.6	22.2±1.6	0.016*
Perimeter (mm)	76.5 ±5.6	69.5±5.4	0.011*
Area (mm²)	451.6 ±57.5	382.3±54.0	0.013*
Left ventricular outflow tract perimeter (mm)	83.9±7.5	64.8±15.4	0.003*
Sinotubular Junction mean diameter (mm)	31.8 ±4.6	29.0±3.3	0.144
Aortic angulation (degree)	49.7 ± 8.7	50.5±15.8	0.895
NCC calcification score (mm ³)	52.2 (22.9,79.1)	156.0 (3.1, 246.2)	0.046*
RCC calcification score (mm ³)	129.6 (51.7, 254.6)	167.5 (85.6, 268.3)	0.412
LCC calcification score (mm ³)	115.7 (37.2, 290.5)	43.5 (4.9, 146.3)	0.295

Table 1 Baseline characteristics of PAI group and Non-PAI group

Data are presented as mean ± standard deviation or median (lower quartile, upper quartile).PAI,

Prosthesis-anterior mitral leaflet interference; NYHA, New York Heart Association; STS, Society of Thoracic

243.6 (127.3, 589.1)

397.3 (144.0, 588.6)

0.656

Surgeons. NCC, Non coronary cusp; RCC, Right coronary cusp; LCC, Left coronary cusp.

Total leaflet calcification score (mm³)

	PAI group (n=9)	Non-PAI group (n=11)	P value
Prosthesis size			0.013*
L23	2/9	9/11	
L26	4/9	2/11	
L29	3/9	0/11	
Implantation depth at NCC (mm)	12.2±3.3	6.2±2.9	<0.001*
Implantation depth at LCC (mm)	14.3±4.7	7.7±3.1	0.002*
Pre dialation	9/9	11/11	NA
Post dilation	1/9	6/11	0.070
Coronary obstruction	0/9	1/11	1.000
New onset atrial fibrillation	0/9	1/11	1.000
New onset LBBB	7/9	3/11	0.070
Need of permanent pacemaker	1/9	2/11	1.000
Major bleeding	0/9	1/11	1.000
≥Moderate perivalvular leakage	5/9	0/11	0.008*
Peak aortic flow velocity (cm/s)	271.7±33.2	273.5±50.5	0.928
Mean aortic valve pressure gradient (mmHg)	15.0±3.8	16.9±7.5	0.497
≥Mild mitral regurgitation	7/9	3/11	0.070
≥Moderate mitral regurgitation	2/9	1/11	0.566

Table 2 Intra-Procedural data and in-hospital outcomes of the two groups.

Data are presented as mean ± standard deviation.

PAI, Prosthesis-anterior mitral leaflet interference; NCC, Non coronary cusp; LCC, Left coronary cusp. LBBB, left bundle branch block. NA, Not Applicable.

	PAI group (n=9)	Non-PAI group (n=11)	P value
30-day outcome			
Peak aortic flow velocity (cm/s)	256.5±42.3	281.7±60.1	0.483
Mean aortic valve pressure gradient (mmHg)	13.6±4.5	17.5 ±7.6	0.312
Mean mitral valve pressure gradient (mmHg)	1.6 ±0.6	1.5 (1.0, 2.1)	0.945
➢Mild mitral stenosis	0/9	0/11	NA
➢Moderate mitral regurgitation	2/9	2/11	0.625
≥Moderate perivalvular leakage	4/9	1/11	0.127
NYHA class III/IV	4/9	1/11	0.127
Stroke	0/9	0/11	NA
All-cause mortality	0/9	0/11	NA
Infective endocarditis	0/9	0/11	NA
Mitral valve perforation	0/9	0/11	NA
12-month outcome			
Peak aortic flow velocity (cm/s)	279.7±22.6	292.6 ±64.1	0.681
Mean aortic valve pressure gradient(mmHg)	15.0±2.9	19.4 ±8.2	0.191
Mean mitral valve pressure gradient (mmHg)	1.9±1.4	1.5 (1.0, 2.0)	0.964
➢Mild mitral stenosis	0/9	0/11	NA
➢Moderate mitral regurgitation	3/9	1/11	0.217
≥Moderate perivalvular leakage	4/9	1/11	0.127
NYHA class III/IV	1/9	0/11	0.450
Stroke	0/9	0/11	NA
All-cause mortality	0/9	0/11	NA
Infective endocarditis	0/9	0/11	NA
Mitral valve perforation	0/9	0/11	NA

Table 3 The 30-day and 12-month clinical outcomes of the two groups

Data are presented as mean ± standard deviation or median (lower quartile, upper quartile).

PAI, Prosthesis-anterior mitral leaflet interference; NYHA, New York Heart Association; NA, Not Applicable.